Trial: 202110179

A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors



Principal Investigator

Hayashi, Robert

Disease Site

Anus; Bones and Joints; Breast; Cervix; Esophagus; Eye and Orbit; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Non-Hodgkin Lymphoma; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid

Learn more about this study at: